{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T22:34:39Z","timestamp":1776292479170,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.nano.2020.102291","type":"journal-article","created":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T19:33:41Z","timestamp":1598124821000},"page":"102291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats"],"prefix":"10.1016","volume":"30","author":[{"given":"Shadabul","family":"Haque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin W.","family":"Pouton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle P.","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B","family":"Ascher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W","family":"Keizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Kaminskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.nano.2020.102291_bb0005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol"},{"issue":"1","key":"10.1016\/j.nano.2020.102291_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.nano.2020.102291_bb0015","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.nano.2016.03.002","article-title":"Disposition and safety of inhaled biodegradable nanomedicines: opportunities and challenges","volume":"12","author":"Haque","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2020.102291_bb0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cocis.2017.06.003","article-title":"Polymer-drug conjugates as inhalable drug delivery systems: a review","volume":"31","author":"Marasini","year":"2017","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"10.1016\/j.nano.2020.102291_bb0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2014.03.012","article-title":"Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy","volume":"183","author":"Kaminskas","year":"2014","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.nano.2020.102291_bb0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jconrel.2011.08.008","article-title":"Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations","volume":"157","author":"Al-Qadi","year":"2012","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.nano.2020.102291_bb0035","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jconrel.2011.12.004","article-title":"Controlled pulmonary drug and gene delivery using polymeric nano-carriers","volume":"161","author":"Beck-Broichsitter","year":"2012","journal-title":"J Control Release"},{"issue":"12","key":"10.1016\/j.nano.2020.102291_bb0040","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/polb.22259","article-title":"Biomedical applications of biodegradable polymers","volume":"49","author":"Ulery","year":"2011","journal-title":"J Polym Sci Part B Polym Phys"},{"issue":"2","key":"10.1016\/j.nano.2020.102291_bb0045","first-page":"1","article-title":"Deposition and biokinetics of inhaled nanoparticles","volume":"7","author":"Geiser","year":"2010","journal-title":"Part Fibre Toxicol"},{"issue":"5","key":"10.1016\/j.nano.2020.102291_bb0050","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1152\/japplphysiol.00514.2002","article-title":"Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer","volume":"94","author":"Geiser","year":"2003","journal-title":"J Appl Physiol"},{"issue":"1","key":"10.1016\/j.nano.2020.102291_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/rtph.1995.1017","article-title":"Lung particle overload: implications for occupational exposures to particles","volume":"21","author":"Oberdorster","year":"1995","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"10.1016\/j.nano.2020.102291_bb0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/jam.1988.1.289","article-title":"Lung clearance of inhaled insoluble and soluble particles","volume":"1","author":"Oberd\u00f6rster","year":"1988","journal-title":"J Aerosol Med"},{"issue":"4","key":"10.1016\/j.nano.2020.102291_bb0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/jamp.2009.0806","article-title":"Influence of particle size and material properties on mucociliary clearance from the airways","volume":"23","author":"Henning","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"4","key":"10.1016\/j.nano.2020.102291_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1601556","article-title":"Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation","volume":"3","author":"Schneider","year":"2017","journal-title":"Sci Adv"},{"issue":"4","key":"10.1016\/j.nano.2020.102291_bb0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/hc0402.104118","article-title":"Passage of inhaled particles into the blood circulation in humans","volume":"105","author":"Nemmar","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.nano.2020.102291_bb0080","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00204-008-0371-1","article-title":"Extrapulmonary translocation of intratracheally instilled fine and ultrafine particles via direct and alveolar macrophage-associated routes","volume":"83","author":"Furuyama","year":"2009","journal-title":"Arch Toxicol"},{"issue":"12","key":"10.1016\/j.nano.2020.102291_bb0085","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/nbt.1696","article-title":"Rapid translocation of nanoparticles from the lung airspaces to the body","volume":"28","author":"Choi","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nano.2020.102291_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1573413714666180313130235","article-title":"Suggested procedures for the reproducible synthesis of Poly(d,l-lactideco- glycolide) nanoparticles using the emulsification solvent diffusion platform","volume":"14","author":"Haque","year":"2018","journal-title":"Current Nanoscience"},{"issue":"5","key":"10.1016\/j.nano.2020.102291_bb0095","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1021\/mp060032e","article-title":"Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats","volume":"3","author":"Boyd","year":"2006","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.nano.2020.102291_bb0100","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1002\/jps.21692","article-title":"Partly-PEGylated poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers","volume":"98","author":"Kaminskas","year":"2009","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.nano.2020.102291_bb0105","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1021\/mp400091n","article-title":"Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent","volume":"10","author":"Ryan","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2020.102291_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2018.01.001","article-title":"A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3 H-labelled structural lipids after pulmonary delivery in rats","volume":"125","author":"Haque","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nano.2020.102291_bb0115","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ejpb.2017.07.005","article-title":"Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers","volume":"119","author":"Haque","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"10.1016\/j.nano.2020.102291_bb0120","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/mp7001208","article-title":"The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers","volume":"5","author":"Kaminskas","year":"2008","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2020.102291_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2019.05.043","article-title":"Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats","volume":"307","author":"Haque","year":"2019","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.nano.2020.102291_bb0130","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI112929","article-title":"Degradation of dipalmitoyl phosphatidylcholine by isolated rat granular pneumocytes and reutilization for surfactant synthesis","volume":"79","author":"Chander","year":"1987","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.nano.2020.102291_bb0135","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1152\/jappl.1987.62.6.2295","article-title":"Degradation and reutilization of alveolar phosphatidylcholine by rat lungs","volume":"62","author":"Fisher","year":"1987","journal-title":"J Appl Physiol"},{"issue":"1","key":"10.1016\/j.nano.2020.102291_bb0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00113-L","article-title":"Mechanisms of macromolecule absorption by the lungs","volume":"19","author":"Patton","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.nano.2020.102291_bb0145","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1513\/pats.200409-049TA","article-title":"The lungs as a portal of entry for systemic drug delivery","volume":"1","author":"Patton","year":"2004","journal-title":"Proc Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.nano.2020.102291_bb0150","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1021\/acsnano.6b08551","article-title":"Inhaled nanoparticles accumulate at sites of vascular disease","volume":"11","author":"Miller","year":"2017","journal-title":"ACS Nano"},{"issue":"18","key":"10.1016\/j.nano.2020.102291_bb0155","first-page":"1","article-title":"Physicochemical characteristics of nanomaterials that affect pulmonary inflammation","volume":"11","author":"Braakhuis","year":"2014","journal-title":"Part Fibre Toxicol"},{"issue":"11","key":"10.1016\/j.nano.2020.102291_bb0160","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1021\/bm201226x","article-title":"Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells","volume":"12","author":"Mura","year":"2011","journal-title":"Biomacromolecules"},{"issue":"1","key":"10.1016\/j.nano.2020.102291_bb0165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.drudis.2019.09.023","article-title":"Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery","volume":"25","author":"Liu","year":"2020","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.nano.2020.102291_bb0170","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.nano.2020.102291_bb0175","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/jam.2006.19.74","article-title":"Ultrafine particle-lung interactions: does size matter?","volume":"19","author":"Kreyling","year":"2006","journal-title":"J Aerosol Med"},{"issue":"3","key":"10.1016\/j.nano.2020.102291_bb0180","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"issue":"6","key":"10.1016\/j.nano.2020.102291_bb0185","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1021\/mp300559v","article-title":"Quantitative detection of PLGA nanoparticle degradation in tissues following intravenous administration","volume":"10","author":"Mohammad","year":"2013","journal-title":"Mol Pharm"},{"issue":"Suppl 5","key":"10.1016\/j.nano.2020.102291_bb0190","first-page":"173","article-title":"Correlation between particle size, in vivo particle persistence, and lung injury","volume":"102","author":"Oberd\u00f6rster","year":"1994","journal-title":"Environ Health Perspect"},{"issue":"12","key":"10.1016\/j.nano.2020.102291_bb0195","doi-asserted-by":"crossref","first-page":"11773","DOI":"10.1021\/acsnano.7b08008","article-title":"A decade of the protein corona","volume":"11","author":"Ke","year":"2017","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.nano.2020.102291_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00600-w","article-title":"Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.nano.2020.102291_bb0205","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12989-017-0223-3","article-title":"Protein corona: implications for nanoparticle interactions with pulmonary cells","volume":"14","author":"Konduru","year":"2017","journal-title":"Part Fibre Toxicol"},{"issue":"43","key":"10.1016\/j.nano.2020.102291_bb0210","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1021\/la502144z","article-title":"Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs","volume":"30","author":"Garbuzenko","year":"2014","journal-title":"Langmuir"},{"issue":"8","key":"10.1016\/j.nano.2020.102291_bb0215","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/acs.molpharmaceut.5b00064","article-title":"Pulmonary delivery of voriconazole loaded nanoparticles providing a prolonged drug level in lungs: a promise for treating fungal infection","volume":"12","author":"Das","year":"2015","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.nano.2020.102291_bb0220","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1021\/mp900215p","article-title":"Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics","volume":"6","author":"Liu","year":"2009","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.nano.2020.102291_bb0225","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1021\/mp300426u","article-title":"Inhaled PLGA particles of prostaglandin E1 ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency","volume":"10","author":"Gupta","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2020.102291_bb0230","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jpba.2017.07.051","article-title":"PLGA ethionamide nanoparticles for pulmonary delivery: development and in vivo evaluation of dry powder inhaler","volume":"145","author":"Debnath","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.nano.2020.102291_bb0235","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.impact.2017.03.003","article-title":"Biokinetics of nanomaterials: the role of biopersistence","volume":"6","author":"Laux","year":"2017","journal-title":"NanoImpact"},{"key":"10.1016\/j.nano.2020.102291_bb0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.addr.2014.02.001","article-title":"Challenges for inhaled drug discovery and development: induced alveolar macrophage responses","volume":"71","author":"Forbes","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.nano.2020.102291_bb0245","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/00498254.2011.632827","article-title":"Interpretation and prediction of inhaled drug particle accumulation in the lung and its associated toxicity","volume":"42","author":"Jones","year":"2012","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.nano.2020.102291_bb0250","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2010.02.014","article-title":"A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung","volume":"75","author":"Nassimi","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"issue":"Suppl 1","key":"10.1016\/j.nano.2020.102291_bb0255","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/08958370903005769","article-title":"Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models","volume":"21","author":"Nassimi","year":"2009","journal-title":"Inhal Toxicol"},{"issue":"9","key":"10.1016\/j.nano.2020.102291_bb0260","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3109\/08958378.2013.810315","article-title":"In vitro and ex vivo toxicological testing of sildenafil-loaded solid lipid nanoparticles","volume":"25","author":"Paranjpe","year":"2013","journal-title":"Inhal Toxicol"},{"key":"10.1016\/j.nano.2020.102291_bb0265","first-page":"2591","article-title":"Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells","volume":"6","author":"Mura","year":"2011","journal-title":"Int J Nanomedicine"},{"issue":"1\u20132","key":"10.1016\/j.nano.2020.102291_bb0270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2014.11.042","article-title":"Surface coating mediates the toxicity of polymeric nanoparticles towards human-like macrophages","volume":"482","author":"Grabowski","year":"2015","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.nano.2020.102291_bb0275","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijpharm.2013.05.025","article-title":"Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells","volume":"454","author":"Grabowski","year":"2013","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.nano.2020.102291_bb0280","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11095-015-1806-z","article-title":"A comparison of the pharmacokinetics and pulmonary lymphatic exposure of a generation 4 PEGylated Dendrimer following intravenous and aerosol administration to rats and sheep","volume":"33","author":"Ryan","year":"2015","journal-title":"Pharm Res"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420301453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420301453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:11:48Z","timestamp":1761549108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963420301453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":56,"alternative-id":["S1549963420301453"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2020.102291","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2020.102291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102291"}}